Social Sciences · Education
Amyloid‑α\nPeptide Formed through Alternative\nProcessing of the Amyloid Precursor Protein Attenuates Alzheimer’s\nAmyloid‑β Toxicity via Cross-Chaperoning
Ariel J. Kuhn (4710417), Ka Chan (17809345), Maria Sajimon (17404488), Stan Yoo (1489777), Vitor Hugo Balasco Serrão (9689609), Jack Lee (497797), Benjamin Abrams (17809348), James S. Nowick (1272555), Vladimir N. Uversky (123421), Christopher Wheeler (17809351), Jevgenij A. Raskatov (1280973)
See on the mapAbstract
Amyloid\naggregation is a key feature of Alzheimer’s disease\n(AD) and a primary target for past and present therapeutic efforts.\nRecent research is making it increasingly clear that the heterogeneity\nof amyloid deposits, extending past the commonly targeted amyloid-β\n(Aβ), must be considered for successful therapy. We recently\ndemonstrated that amyloid-α (Aα or p3), a C-terminal peptidic\nfragment of Aβ, aggregates rapidly to form amyloids and can\nexpedite the aggregation of Aβ through seeding. Here, we advance\nthe understanding of Aα biophysics and biology in several important\nways. We report the first cryogenic electron microscopy (cryo-EM)\nstructure of an Aα amyloid fibril, proving unambiguously that\nthe peptide is fibrillogenic. We demonstrate that Aα induces\nAβ to form amyloid aggregates that are less toxic than pure\nAβ aggregates and use nuclear magnetic resonance spectroscopy\n(NMR) to provide insights into specific interactions between Aα\nand Aβ in solution. This is the first evidence that Aα\ncan coassemble with Aβ and alter its biological effects at relatively\nlow concentrations. Based on the above, we urge researchers in the\nfield to re-examine the significance of Aα in AD.